Double protection in patients with a massive thrombus in the infarct-related artery - a single-center retrospective

Piotr Chodór1, Grzegorz Honisz1, Krzysztof Wilczek2

  • 1Silesian Center for Heart Diseases, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Zabrze, Poland.

Insights

Double protection (DP) using manual thrombectomy with a distal protection device is a safe and feasible approach for patients experiencing ST-segment elevation myocardial infarction (STEMI) with massive thrombus (MT). Further studies are needed to confirm its efficacy in improving outcomes for these critical cardiac events.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • ST-segment elevation myocardial infarction (STEMI) involves thrombus formation on atherosclerotic plaques.
  • Massive thrombus (MT) in STEMI can lead to severe complications like extensive myocardial infarction (MI) and impaired reperfusion.
  • Current treatments for coronary thrombi exist, but the efficacy of double protection (DP) combining manual thrombectomy (MTH) with a distal protection device (DPD) remains unevaluated.

Purpose of the Study:

  • To evaluate the outcomes of the double protection (DP) strategy in patients presenting with STEMI and MT.
  • To assess the safety and feasibility of DP as a treatment for STEMI with MT.

Main Methods:

  • A study included fourteen patients diagnosed with STEMI and MT.
  • All patients underwent primary percutaneous coronary intervention (PPCI) utilizing the DP technique.
  • DP involved manual thrombectomy (MTH) combined with a distal protection device (DPD).

Main Results:

  • Inferior MI was prevalent, affecting 12 (85.8%) patients.
  • Stent implantation was performed in 13 (92.8%) patients.
  • A high thrombus burden was observed, with Thrombolysis In Myocardial Infarction (TIMI) Thrombus Grade 5 in 11 (78.6%) and Grade 4 in 3 (21.4%) patients, and a median thrombus length of 39.1 mm.
  • Complete reperfusion (TIMI flow 3) was achieved in 11 (78.6%) patients, with TIMI flow 2 in 3 (21.4%).
  • Myocardial Blush Grade 3 was noted in 5 (35.7%) patients with TIMI flow 3.
  • Significant ST-segment elevation resolution (>50%) occurred in 13 (92.8%) patients.
  • No in-hospital adverse events such as myocardial rupture, stroke, or death were reported.

Conclusions:

  • The double protection (DP) strategy, incorporating MTH and DPD, is a safe and feasible procedural option for managing patients with STEMI and MT.
  • While initial results suggest safety, further extensive research and clinical trials are necessary to definitively establish the efficacy of DP in improving long-term patient outcomes.
Abstract